Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 6/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9943968 | 0.83 | CYP1A2 (0.41) | CYP1A2CYP3A4TSHRCLK4HSD17B10 | |
| SCHEMBL83123 | 0.76 | GSK3B (0.50) | CYP1A2GSK3BCYP2D6 | |
| SCHEMBL137966 | 0.74 | GSK3B (0.60) | GSK3BCYP2D6 | |
| SCHEMBL9943993 | 0.70 | GSK3B (0.49) | CYP1A2GSK3BCYP2D6 | |
| SCHEMBL1673943 | 0.68 | GSK3B (0.52) | CYP1A2CLK4GSK3BCYP2D6 | |
| SCHEMBL9944000 | 0.67 | SMN1; SMN2 (0.49) | CYP1A2CYP3A4TSHRGSK3BCYP2D6 | |
| SCHEMBL844040 | 0.63 | KDM4E (0.40) | TSHRHSD17B10ALDH1A1 | |
| SCHEMBL17382565 | 0.62 | MAPT (0.42) | CYP1A2CYP3A4TSHRHSD17B10 | |
| SCHEMBL81975 | 0.62 | RXFP1 (0.38) | GSK3B | |
| SCHEMBL696759 | 0.61 | BACE1 (0.41) | CLK4ALDH1A1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940738-B2 | Pyrimidone compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940738-B2 | Pyrimidone compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | disclosed |
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | disclosed |
| EP-2464639-A1 | PYRIMIDONE DERIVATIVES USED AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | MAPT, PRNP, PSEN1 | CYP1A2 2029/4885CYP3A4 3607/4885TSHR 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.